Michele Pighi, Fabrizio Tomai, Simone Fezzi, Gabriele Pesarini, Alessandro Petrolini, Leonardo Spedicato, Giuseppe Tarantini, Marco Ferlini, Paolo Calabrò, Bruno Loi, Valeria Ferrero, Maria Natalia Tovar Forero, Joost Daemen, Flavio Ribichini
BACKGROUND: Cardiac allograft vasculopathy (CAV) is still the main drawback of heart transplantation (HTx) and percutaneous coronary intervention (PCI) is a palliative measure because of the high incidence of failure. OBJECTIVE: This study aimed to investigate the safety and efficacy of bioresorbable scaffolds (BRSs) as potential novel therapeutic tool for the treatment of coronary stenoses in CAV. METHODS: This is a multicenter, single-arm, prospective, open-label study (CART, NCT02377648), that included patients affected by advanced CAV treated with PCI and second-generation ABSORB BRS (Abbott Vascular)...
January 3, 2024: Clinical Research in Cardiology: Official Journal of the German Cardiac Society